N/A N=30 Functional Performance Evaluation of NU-FlexSIV Socket
Amputation · Artificial Limbs
Primary: Socket Comfort Score (SCS) Between IC Socket and NU-FlexSIV Sockets at 7 Weeks. — 8.5; 6.8 score on a scale — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=23 Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt Disease
Stargardt Disease · Macular Atrophy
Primary: Change in Electrical Response of the Retina to a Flash of Light, as Measured by Electroretinogram — -12.23; 68.00; 96.69 percent suppression
N/A N=117 A Post-Market Evaluation of LipiFlow Treatment in Cataract Surgery Practice
Cataracts · Meibomian Gland Dysfunction (MGD)
Primary: Mean Monocular UCDVA (Uncorrected Distance Visual Acuity) — 0.08; 0.07 LogMAR
N/A N=18 Wearable Vibration Device to Prevent Bone Loss in Postmenopausal Women--Aim 2
Osteopenia
Primary: Percent Change in Blood-based Biomarker of Bone Loss — 8.8; -5.4 Percent change — p=<0.001
N/A N=489 An Observational Outcomes Study for Autologous Cell Therapy Among Patients With COPD and Interstitial Lung Disease
COPD · Interstitial Lung Disease
Primary: Change in Quality of Life (QOL) From Baseline — 35.35; 27.96; 26.87 score on a scale
Phase 2 N=113 Trial of Clopidogrel After Surgery for Coronary Artery Disease (CASCADE Trial)
Atherosclerosis
Primary: Vein Graft Intimal Area — 4.1; 4.5 mm
Phase 4 N=201 ABSORICA in Patients With Severe Recalcitrant Nodular Acne
Acne
Primary: Active Treatment Period: Total Acne-Specific Quality of Life Score at Week 20 — 100.7 score
N/A N=380 Evaluation of Non-Invasive Hemoglobin in Trauma Patients
Trauma
Primary: SpHb's Ability to Detect Critical Drops
Phase 2 N=65 AllogeneiC Human Mesenchymal Stem Cells (hMSC) in Patients With Aging FRAilTy Via IntravenoUS Delivery
Frailty
Primary: Incidence of Any Treatment Emergent - Serious Adverse Events (TE-SAEs) — 0; 0; 0; 0 Incidents
Phase 2 N=67 Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy
Epilepsy, Focal Seizures, Partial Seizures
Primary: Change From Baseline in Log-Transformed Seizure Frequency During Weeks 8 to 24 of Treatment — -0.43; -0.58 log(seizure/28 days) — p=0.5053
Phase 4 N=27 Intrathecal (IT) Baclofen Drug Distribution
Muscle Spasticity
Primary: Subjects Experiencing Maximal MAS Change From Baseline - Spasticity of Cerebral Origin — 8; 7; 3; 3 Participants
Phase 4 N=53 Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy
Myocardial Fibrosis · Hypertrophic Cardiomyopathy
Primary: Absolute Change in Serum Markers of Collagen Turnover (Micrograms/L) Over a One-year Follow-up Period in the Spironolactone Group Compared to Placebo. — 2.1; 2.1; 0.7…
N/A N=40 Open Label Study Using OsteoProbe System
Adverse Effects in the Use of the OsteoProbe System
Primary: The Number of Participants With Reported Device Related Serious Adverse Events. — 0 Participants
Phase 4 N=86 TAP Block Catheters vs Liposomal Bupivacaine for Pain Control After Colorectal Surgery
Colorectal Surgery · TAP Blocks
Primary: Mean Opioid Consumption in Morphine Opioid Equivalents in mg — 112.12; 97.95 IV morphine equivalents (mg)
N/A N=68 Effects of Mouth-opening Training on the Maximum Interincisal Opening
Oral Cancer
Primary: TheraBite Range-of-Motion Scale — 27.43; 26.57; 27.33; 16.17 units on a scale